ALX Oncology at H.C. Wainwright conference: two drug bets near key tests
On September 14, 2026, ALX Oncology presented its two-drug strategy at the H.C. Wainwright 28th Annual Global Investment Conference. The company aimed to have both programs, evorpacept and ALX2004, ready for registration studies within 12 months. Evorpacept, a CD47 blocker, demonstrated a favorable safety profile in over 800 patients and showed a biomarker signal tied to CD47 expression.
ALX2004, an EGFR-directed TOP1 antibody-drug conjugate, is being tested in four tumor types. The company has $153 million in cash, which it expects will cover operations through the first half of 2028. Management highlighted the importance of biomarker selection and companion diagnostic work, which could support smaller phase III studies than traditionally seen in oncology.
The company's focus is on two internally developed programs that could each lead to later-stage development.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
